Advertisement

Topics

Positive Opinion Issued In EU For Herzuma Trastuzumab Biosimilar

05:05 EST 18 Dec 2017 | Pharmaceutical Processing

Celltrion’s Herzuma (trastuzumab biosimilar) receives positive opinion from EMA’s CHMP for early breast cancer, metastatic breast cancer, and metastatic gastric cancer
Contributed Author: 
Celltrion, Inc.
Topics: 

Original Article: Positive Opinion Issued In EU For Herzuma Trastuzumab Biosimilar

NEXT ARTICLE

More From BioPortfolio on "Positive Opinion Issued In EU For Herzuma Trastuzumab Biosimilar"

Quick Search
Advertisement
 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...